Home
Resources
Publications
Experimental Thymidine Kinase-Deficient HSV-1 Keratitis: Therapeutic Attempts

Experimental Thymidine Kinase-Deficient HSV-1 Keratitis: Therapeutic Attempts

P C Maudgal, E De Clercq, P Huyghe

Curr Eye Res. 1987 Apr;6(4):579-84.

PMID: 2953558

Abstract:

Trifluridine (TFT) and a structurally related analogue, 5-fluoro-2'-deoxyuridine (FDU), were investigated for their efficacy in the topical treatment of experimental keratitis caused by thymidine kinase-positive (TK+) and thymidine kinase-deficient (TK-) herpes simplex virus type 1 (HSV-1) strains. Bromovinyldeoxyuridine (BVDU) was used as a reference compound. Both 0.2% BVDU and 0.2% TFT eyedrops produced a highly significant healing of TK+HSV-1 keratitis as compared to the placebo and 0.2% FDU eyedrops (P much less than 0.005), whereas the latter compound did not differ from placebo eyedrops. In the treatment of TK HSV-1 keratitis, none of the drugs exhibited a beneficial healing effect, although the virus strain used was inhibited in vitro by TFT and FDU at a very low concentration (0.02-0.04 microgram/mL).

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP14599463	Trifluridine Related Compound A		14599-46-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: